GastroCE
LECTURECME

Effective Disease Management of Ulcerative Colitis: Where Are We Now and What Does the Future Hold?

Author(s)/Faculty: Gary R. Lichtenstein, MD, FACP, FACG, AGAF; Silvio Danese, MD, PhD; Bruce E. Sands, MD, MS; Douglas C. Wolf, MD
Release Date: 7/13/2015Expiration Date: 6/14/2018
Credit Type: CMENumber of Credits: 2
Content Type: LectureProvider: Vindico Medical Education
Ulcerative colitis (UC) is the most common inflammatory bowel disease (IBD) worldwide, with approximately 600,000 Americans living with UC. Ulcerative colitis is characterized by an overactive immune response to the gut enteric flora, resulting in bowel inflammation and ulceration. As one study demonstrated that approximately 80% of studied patients with IBD received suboptimal therapy, there is substantial room for improvement in the care of patients with IBD. Several agents with a variety of mechanisms of action are now in clinical development or available for the treatment of UC. As the therapeutic landscape for UC continues to evolve, physicians need to be aware of how these agents can be used to optimize outcomes for patients. This CME activity addresses the mechanisms of action, efficacy, safety, and recommended usage of available and emerging therapies for the management of moderate-to-severe ulcerative colitis. Preclinical and clinical data on novel immunomodulators for UC will be discussed.